US Patent

US8273892 — Salt and crystalline forms thereof of a drug

Composition of Matter · Assigned to Abbott Laboratories · Expires 2026-08-06 · 0y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of a drug, methods of making them, and compositions containing them, assigned to Abbott Laboratories.

USPTO Abstract

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Drugs covered by this patent

delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

Patent Metadata

Patent number: US8273892
Jurisdiction: US
Classification: Composition of Matter
Expires: 2026-08-06
Drug substance claim: Yes
Drug product claim: No
Assignee: Abbott Laboratories
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.